Reuters Sources: AgiBot Eyes HK$40–50B Valuation for Hong Kong Listing路透消息：智元机器人港股IPO估值目标锁定400亿至500亿港元区间
Reuters sources, picked up by Cryptopolitan and flagged in the weekly roundup at RoboZaps, put AgiBot's Hong Kong IPO valuation target at HK$40 billion to HK$50 billion — roughly $5.1 billion to $6.4 billion at current rates. The company is expected to float 15% to 25% of its shares. Those are the only hard numbers in the public record right now, and they come from anonymous sources rather than any prospectus filing. Watch the sentence, not the speech.
AgiBot (智元机器人) disclosed its Hong Kong listing intention earlier in 2025. Alongside Unitree, it holds a combined domestic market share approaching 80% of China's humanoid robot segment, per analyst estimates widely cited in Chinese industry media. That duopoly framing matters because both companies are now on parallel IPO tracks — Unitree toward the STAR Market in Shanghai, AgiBot toward Hong Kong — which means the sector is about to get its first real public-market price discovery after years of private-round opacity.
The policy backdrop is doing real work here. Beijing's standing target — 10,000 working humanoid robots deployed across industrial settings by end of 2025 — creates a procurement floor that neither company has to manufacture from thin air. The mandate is real: it appears in Ministry of Industry and Information Technology guidance documents and has been echoed in provincial implementation plans. Whether 10,000 units represents genuine utilization or showcase installation is a separate question, but for IPO marketing purposes the number is unambiguously useful.
The valuation range, if achieved, would represent a premium over AgiBot's last known private-round pricing. That premium reflects a straightforward supply-and-demand argument: there is currently almost no pure-play humanoid equity available to international institutional investors outside of Boston Dynamics' private structure and a handful of small-cap adjacencies. AgiBot and Unitree together would change that. The scarcity premium is real, even if the underlying revenue base remains thin relative to the implied multiples.
What the Reuters sourcing does not tell you: the timeline to filing, the identity of lead underwriters, the revenue and gross-margin figures that would anchor any serious valuation analysis, or whether the 15%–25% float range reflects a company preference or a bank recommendation. A source-based valuation figure from an IPO that has not yet produced a prospectus is, structurally, a marketing data point. That does not make it false; it makes it incomplete.
The Hong Kong exchange venue is itself a signal worth parsing. Hong Kong gives AgiBot access to international institutional capital while keeping the listing within a Chinese-law-friendly jurisdiction — an increasingly standard choice for tech companies navigating U.S. listing restrictions. It also puts the offering in direct line of sight for Middle Eastern sovereign funds and Southeast Asian family offices that have been actively rotating into Chinese tech equity since 2024. The HK$40–50 billion range may be calibrated as much to those buyers as to any intrinsic DCF.
The AIPM intensity score of 122 on this story reflects genuine policy-market coupling: the humanoid deployment mandate, the dual-listing momentum, and the absence of any comparable public-market reference point all compound. That coupling is exactly why the valuation figure travels so fast through secondary coverage even without a prospectus to anchor it.
Watch for: the formal listing application (上市申请) filing on the Hong Kong Stock Exchange's disclosure portal, which will be the first document to contain audited financials and a real share structure. Until that filing appears, every valuation figure in circulation — including this one — is a negotiating position, not a price.